Italia Markets open in 1 hr 42 mins
Dow Jones
32.237,53 +132,33 (+0,41%) Nasdaq
11.823,96 +36,56 (+0,31%) Nikkei 225
27.502,67 +117,42 (+0,43%) EUR/USD
1,0768 +0,0003 (+0,0323%) BTC-EUR
25.866,82 +275,19 (+1,08%) CMC Crypto 200
606,12 -12,27 (-1,98%)
Arrowhead Pharmaceuticals, Inc. (0HI3.L)
LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
Alla chiusura: 08:08PM BST
| Chiusura precedente | 23,69 |
| Aperto | 0,00 |
| Denaro | 0,00 x N/D |
| Lettera | 0,00 x N/D |
| Min-Max giorno | 0,00 - 0,00 |
| Intervallo di 52 settimane | |
| Volume | |
| Media Volume | N/D |
| Capitalizzazione | 2,346B |
| Beta (5 anni mensile) | 1,01 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,00 |
| Prossima data utili | 08 mag 2023 - 12 mag 2023 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
- GlobeNewswire
Royalty Pharma Agrees to Acquire Royalty Interest in Olpasiran From Arrowhead for $250 million and Future Milestones
Olpasiran is an siRNA therapeutic being developed by Amgen to reduce risk of cardiovascular disease Arrowhead retains rights to $400 million in development, regulatory and sales milestone payments potentially due from Amgen from the 2016 out licensing agreement NEW YORK and PASADENA, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Arrowhead today announced that Royalty Pharma has acquired a royalty interest in Amgen’s olpasiran from Arrowhead Pharmaceuticals (Nasd
© 2023 Yahoo. Tutti i diritti riservati.
